The Exchange has sought clarification from Aurobindo Pharma Limited with respect to recent news item captioned Pharma stocks slump as Trump shoots letters to 17 global drug majors seeking lower prices. The response from the Company is attached.
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
NSE sought clarification from Aurobindo Pharma after a Moneycontrol article reported that pharma stocks slumped because Trump sent letters to 17 global drug companies seeking lower drug prices. Aurobindo Pharma responded on August 1, 2025, stating it has not received any communication from Trump or any related party. The company said it is not aware of any negotiations or events involving it that could explain the movement in its share price. It also confirmed there is no undisclosed price-sensitive information that needs to be shared with the exchanges under SEBI regulations.
This is a routine clarification to address an exchange query, not a company-specific negative development. The stock movement was driven by a broader sector news event, and Aurobindo has confirmed no company-specific trigger. Short-term volatility may continue until sector sentiment stabilizes, but there is no material impact on the company's fundamentals from this announcement.